This $1,063,710 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The grant will fund research conducted by The Johns Hopkins University to investigate the epigenetic mechanisms controlling sensitivity to single-stranded DNA lesions and associated mutagenesis. The primary objectives are to define the role of the histone variant MacroH2A1 in regulating DNA repair processes, determine the impact on cancer risk and...
This Project Grant award, with the ID F31CA287658, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award aims to investigate the direct transcriptional targets and epigenetic mechanisms of the MECOM gene, which plays a critical role in high-risk acute myeloid leukemia (AML). The primary recipient of this $165,247 award is Harvard Medical School, which will conduct research to identify MECOM's direct genetic targets...
This $655,000 federal Project Grant award, provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, funds research to identify and overcome resistance after donor-derived ex vivo expanded natural killer (NK) cells and haploidentical hematopoietic cell transplantation (haplo-HCT) in children and young adults with high-risk acute myeloid leukemia (AML). The grant, awarded to The Johns Hopkins University, will support advanced...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $443,220 to the Beckman Research Institute of the City of Hope to investigate the role, mechanism, and therapeutic potential of the RNA methyltransferase METTL1 in acute myeloid leukemia (AML). The 5-year project aims to consolidate the importance of METTL1 function in AML pathogenesis, understand how the METTL1/tRNA/HCK signaling axis facilitates leukemia stem cell...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to identify novel gene drivers that contribute to therapy resistance and disease relapse in acute myeloid leukemia (AML). The $458,698 award to the Regents of the University of Michigan, effective March 10, 2025, will fund a 5-year project to study genes that confer growth advantages to leukemia cells and enable AML relapse despite initial treatment response. The research aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the University of Virginia to study the role of long noncoding RNAs in acute myeloid leukemia (AML), a highly fatal blood cancer. The key objectives are to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. The research aims to provide insight into the functions of enhancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by The Johns Hopkins University to elucidate the role of the HMGA1 gene in pancreatic ductal adenocarcinoma (PDAC) progression and tumor microenvironment interactions. The $431,561 award, spanning 7/1/2024 - 6/30/2029, will fund investigations into HMGA1-dependent mechanisms driving tumor growth, stromal formation, and immune evasion in PDAC, with the goal of identifying...
The National Cancer Institute (NCI) awarded a 3-year, $576,720 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Van Andel Research Institute (VAI) located in Grand Rapids, Michigan. The grant supports research to understand how KMT2A oncoproteins contribute to lineage switching and non-genetic heterogeneity in high-risk KMT2A-rearranged acute leukemias. Specifically, the project aims to (1) identify KMT2A oncoprotein-regulated genes that promote intra-tumoral...
The Johns Hopkins University was awarded a $1,170,746 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to investigate the polyaneuploid cancer cell state and its role in mediating multitherapy resistance in cancer. The three-year award, effective August 15, 2022 through August 14, 2025, will support research into transforming healthcare for service members and the public through innovative biomedical...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $686,937 to The University of Texas Southwestern Medical Center to support research focused on uncovering therapeutic vulnerabilities in acute myeloid leukemia (AML) through mechanistic interrogation of MECOM activity. The research aims to 1) define essential co-regulators and direct targets of MECOM, a transcription factor that is essential for AML maintenance, and 2)...
The Johns Hopkins University was awarded a $243,590 Project Grant under the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) federal grant program. The objective of this 3-year grant, awarded starting December 1, 2024, is to elucidate the role of the chromatin regulator HMGA1 in driving leukemogenesis and therapy resistance in KMT2A-rearranged acute myeloid leukemia (AML). Specifically, the research aims to define how HMGA1 drives leukemogenesis and chemoresistance, and to determine how HMGA1 induces expression of pro-leukemogenic HOX genes and represses the CDKN1A tumor suppressor in KMT2A-rearranged AML. This work could lead to the development of novel therapeutic strategies for this aggressive and treatment-resistant form of leukemia.